Juliet Gatobu, APRN
Gerontology · San Antonio, TXNPI 1245711050
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.6% of the total across 322 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 13 manufacturers reported payments, led by Teva Pharmaceuticals USA, Inc. at 32.3% of the total. Among gerontology clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 322 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Teva Pharmaceuticals USA, Inc.$2K
- Alkermes, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- Vanda Pharmaceuticals Inc.$366
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$285
- Janssen Scientific Affairs, LLC$282
- plus $584 from 7 others
What the payments were for
- Food & beverage$6,64695%
- Education$3775%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Teva Pharmaceuticals USA, Inc. | 86 | $2,268 |
| Alkermes, Inc. | 99 | $1,692 |
| Neurocrine Biosciences, Inc. | 91 | $1,548 |
| Vanda Pharmaceuticals Inc. | 8 | $366 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 7 | $285 |
| Janssen Scientific Affairs, LLC | 2 | $282 |
| Avanir Pharmaceuticals, Inc. | 10 | $188 |
| Otsuka America Pharmaceutical, Inc. | 9 | $187 |
| E.r. Squibb & Sons, L.L.C. | 6 | $144 |
| Sunovion Pharmaceuticals Inc. | 1 | $26 |
| Amgen | 1 | $18 |
| Acerus Pharmaceuticals Corporation | 1 | $13 |
| Johnson & Johnson | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,349
- INGREZZA$391
- UZEDY$365
- INVEGA SUSTENNA$282
- Fanapt$247
- Austedo XR$242
- CAPLYTA$127
- AJOVY$125
How this compares
$7,023 in reported general payments places this provider in the 95th percentile of 653 gerontology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| IngrezzaValbenazine Tosylate | 181 | $1,489,601 |
| AustedoDeutetrabenazine | 125 | $1,134,186 |
| Invega SustennaPaliperidone Palmitate | 240 | $852,247 |
| Abilify MaintenaAripiprazole | 163 | $479,516 |
| UzedyRisperidone | 166 | $437,303 |
| LybalviOlanzapine/Samidorphan Malate | 213 | $356,905 |
| AristadaAripiprazole Lauroxil | 81 | $254,554 |
| Austedo XrDeutetrabenazine | 36 | $189,912 |
| FanaptIloperidone | 67 | $166,239 |
| RexultiBrexpiprazole | 104 | $148,350 |
| VraylarCariprazine Hcl | 57 | $83,667 |
| CaplytaLumateperone Tosylate | 46 | $80,783 |
| NuedextaDextromethorphan Hbr/Quinidine | 52 | $80,269 |
| Naltrexone Hcl | 306 | $58,372 |
| PerserisRisperidone | 20 | $58,030 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo, Uzedy, Austedo Xr | $2,268 | $1,761,401327 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $1,548 | $1,489,601181 claims |
| Johnson & JohnsonInvega Sustenna | $9 | $852,247240 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $187 | $627,866267 claims |
| Alkermes, Inc.Lybalvi, Aristada | $1,692 | $611,459294 claims |
| Vanda Pharmaceuticals Inc.Fanapt | $366 | $166,23967 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $285 | $80,78346 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $188 | $80,26952 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 653 gerontology providers in Texas.
Other gerontology in San Antonio
- Cecilia OrtizSan Antonio$13K
- Bianca LopezSan Antonio$11K
- Alexis SantangeloSan Antonio$9K
- Ashlee DuggerSan Antonio$7K
- Amy RomickSan Antonio$5K
- Diana GarzaSan Antonio$4K
- Kimberly WelchCoppell$113K
- Tiffany KesslerDallas$84K
- Jennifer WestFort Worth$67K
- Bailey EstesAbilene$34K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.